Cardiff Oncology Q1 FY26 net loss narrows to $12.3 million; revenue drops to $41,000

• Cardiff Oncology posted a net loss of $12.3 million for three months ended March 31, 2026, while net cash used in operating activities totaled $12.29 million.
• Revenue fell to $41,000 from royalties, down from $109,000 a year earlier.
• Research and development expense dropped to $6.77 million from $10.48 million, primarily on lower clinical trial expenses and reduced preclinical activities.
• Selling, general and administrative expense climbed to $6.13 million from $4.01 million, driven by employee severance costs and stock-option modifications tied to severance agreements.
• Cash, cash equivalents and short-term investments totaled $46.1 million as of March 31, 2026; management expects funding into first-quarter 2027 and flagged substantial doubt about its ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213037-26-000011), on May 14, 2026, and is solely responsible for the information contained therein.